2 Einträge gefunden

1. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

   1. Warren, R B
   2. Carrascosa, J M
   3. Fumero, E
   4. Schoenenberger, A
   5. Lebwohl, M G
   6. Szepietowski, J C
   7. Reich, K

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

   1. Reich, K
   2. Warren, R B
   3. Iversen, L
   4. Puig, L
   5. Pau-Charles, I
   6. Igarashi, A
   7. Ohtsuki, M

   2020 - Forschungsinformationssystem des UKE